RxDoctor Payments Data

John Appiott, DO

Family Medicine · Federalsburg, MDNPI 1669440681

Payments from drug & device makers

$1,620in general payments, 2019–2025

Across 86 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$214
  • Novo Nordisk$192
  • AstraZeneca$167
  • Lilly USA, LLC$161
  • Astellas Pharma US Inc$132
  • Boehringer Ingelheim$113
  • plus $641 from 12 others

What the payments were for

  • Food & beverage$1,620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,620 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$171,599
Medicare patients
322
Services billed
1,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin77$78,216
EliquisApixaban78$66,833
OzempicSemaglutide63$64,950
TrulicityDulaglutide42$64,526
JanuviaSitagliptin Phosphate41$27,420
MounjaroTirzepatide16$19,930
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$18,802
Tresiba Flextouch U-100Insulin Degludec24$12,941
Famotidine105$9,899
FarxigaDapagliflozin Propanediol14$9,800
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$7,631
Breo ElliptaFluticasone/Vilanterol14$6,737
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$6,368
MyrbetriqMirabegron13$5,729
Advair HfaFluticasone Propion/Salmeterol12$5,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$161$84,45758 claims
Boehringer IngelheimJardiance$113$78,21677 claims
PfizerEliquis$214$66,83378 claims
Novo NordiskOzempic$192$64,95063 claims
MerckJanuvia$29$27,42041 claims
GSKTrelegy Ellipta, Breo Ellipta$36$25,53935 claims
AstraZenecaFarxiga$167$9,80014 claims
Astellas Pharma US IncMyrbetriq$132$5,72913 claims
AbbVieSynthroid$14$2,53039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Federalsburg

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →